FDA Launches Expedited IND Pilot Under Operation TrialBlazer — Applications Open Through October 30, 2026
On September 15, 2026, the FDA announced the final design of the Expedited Investigational New Drug (IND) Pilot and opened applications — the first major operational milestone of HHS's clinical-trials reform push since "Operation TrialBlazer" launched June 22 (FDA Launches Expedited IND Pilot Under Operation TrialBlazer — Applications Open Through October 30, 2026). The pilot pairs drug sponsors with Qualified Research Institutions (QRIs) to speed first-in-human trial starts: "The FDA will accept applications to participate in the pilot until October 30, 2026," and "FDA expects that 8–10 Sponsor-QRI pairs will be selected to participate in the initial pilot cohort."
The stated rationale is competitive: "Currently, first-in-human clinical trials may take up to two years to complete in the United States. The same types of trials are completed much faster in China and Australia, threatening America's leadership in scientific innovation.1" Mechanically, QRIs bring "specialized and substantial scientific expertise to the IND application preparation process," enabling rolling review of IND components during the pre-IND phase rather than an all-at-once submission — designed to surface problems before the 30-day IND clock, reducing the risk of a clinical hold. The FDA stresses it "retains full regulatory authority throughout the program."
Acting FDA Commissioner Kyle Diamantas: "The pilot not only pairs industry innovators with top research institutions to accelerate high-quality data being submitted to the FDA, it also tests if the partnership can accelerate what happens after the FDA allows a clinical trial to proceed." The agency frames the pilot as evidence-generating for a possible future formal accreditation model for QRIs — meaning this 8–10 pair cohort is a policy experiment whose results could reshape early-stage development more broadly.
-
An instance of Geopolitical competition drives the wholesale acceleration of early-stage trials. — The stated rationale for the expedited IND pilot is geopolitical fear of ceding early-stage trial leadership to foreign rivals. ↩︎